Cargando…
Faldaprevir for the Treatment of Hepatitis C
The current treatments for chronic hepatitis C virus (HCV) genotype 1 infection are combinations of direct-acting antivirals, and faldaprevir is one of the new generation of HCV NS3/4A protease inhibitors. At the end of 2013, the US Food and Drug Administration (FDA) approved the HCV NS3/4A protease...
Autores principales: | Kanda, Tatsuo, Yokosuka, Osamu, Omata, Masao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394460/ https://www.ncbi.nlm.nih.gov/pubmed/25749475 http://dx.doi.org/10.3390/ijms16034985 |
Ejemplares similares
-
Treatment of hepatitis C virus infection in the future
por: Kanda, Tatsuo, et al.
Publicado: (2013) -
Hepatitis C Virus and Hepatocellular Carcinoma
por: Kanda, Tatsuo, et al.
Publicado: (2013) -
New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
por: Kanda, Tatsuo, et al.
Publicado: (2014) -
Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014) -
Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review
por: Kanda, Tatsuo, et al.
Publicado: (2019)